We are honored to be ranked second by @forbes.com as one of America’s Best Large Employers 2026. The distinction reflects employee feedback on workplace culture, benefits and opportunities for advancement at St. Jude. ow.ly/Lbqb50Ycz1C

On World Cancer Day, St. Jude recognizes the progress taking shape through the Global Platform for Access to Childhood Cancer Medicines. The initiative, developed with @who.int, supports efforts to build consistent, evidence-based care for children with cancer.

The 12th season of The Science of Childhood Cancer begins February 5th. For the next 15 weeks, leading experts across the spectrum of pediatric cancer research will give lectures on Thursdays at 12pm ET / 1 pm CT.

Childhood cancers are biologically distinct from adult cancers. These diseases often form because normal developmental processes go wrong, which means adult treatments do not work the same in children. See how research at St. Jude is reshaping this landscape: ow.ly/sZWL50Y4xoH

Infectious diseases remain one of the greatest threats to children. As a WHO Collaborating Center for Influenza, St. Jude helps inform global flu vaccine decisions through year-round surveillance and data sharing.

St. Jude congratulates Shannon McKinney-Freeman, PhD, on being named the 2025 Postdoctoral Association Mentor of the Year. Nominated by four mentees, McKinney-Freeman is recognized for her dedication to advancing the next generation of scientists. #MentoringMonth

Recent findings from the IMPAACT Network study show adolescents with HIV in five countries safely switched from daily oral meds to all-injectable treatment every 2 months, maintaining viral suppression. 100% of patients in the trial preferred injectables. ow.ly/nUQQ50XXvQl

Join our webinar on Feb 4, Improving Outcomes for Children with Serious Illness through Applied Qualitative Research Hosted by @stjuderesearch.bsky.social in collaboration with @thelancetoncol.bsky.social and @thelancethaem.bsky.social 🖱️Register here: stjudeglobal.zoom.us/meeting/regi...

For decades, the mystery of how DICER1 mutations promote pediatric rhabdomyosarcoma remained unsolved. Mark Hatley, MD, PhD, and his lab cracked the case, powered by advancements in single-cell RNA sequencing, revealing new paths for intervention. https://ow.ly/UiCG50XU294

Scientists discovered cancer cells use interactive LINE-1 retrotransposon regions to reshape 3D genome architecture, enhancing oncogenic gene expression. This mechanism links LINE-1 activity to cancer development & highlights potential therapeutic targets. ow.ly/qVN650XS0MN

2025 brought new milestones in research, care, education and global partnership at St. Jude. This year’s achievements set the stage for new advances in 2026 and beyond as we continue working to improve the lives of children everywhere. #HappyNewYear #StJude

In 2025, St. Jude advanced pediatric cancer care by supporting context-specific therapies for medulloblastoma, identifying new strategies to overcome resistance in high-risk leukemia and informing combination immunotherapy approaches for neuroblastoma.

Looking to advance your skills in biostatistics and make a meaningful impact? Apply for the Summer 2026 Biostatistics Internship at St. Jude. Applications are open until Jan 9. Learn more & apply: www.stjude.org/education-tr...

This holiday season, we celebrate the hope that shines through every breakthrough and every child’s smile. The mission of St. Jude lives in all of us through our shared commitment to finding cures and saving children, just like the spirit of the season.

Recent findings show that differences in drug efficacy arise from how quickly agonists drive GPCRs through activation steps, rather than their final conformational state. These insights advance our understanding of GPCR signaling and inform future drug development. ow.ly/ez1F50XNnjk

This year, St. Jude advanced structural biology research by revealing key mechanisms in chromatin remodeling and cell migration, informing new strategies for gene regulation and cellular therapies.

Researchers have revealed a hidden intermediate state at the center of Src kinase function. This fleeting state is vital for rapid cell migration and T-cell activation, opening new possibilities for targeting kinases. ow.ly/HWe450XLHbg

Atypical teratoid rhabdoid tumor (ATRT) is a rare, aggressive brain cancer diagnosed in fewer than 100 U.S. children annually. St. Jude researchers found that combining idasanutlin and selinexor to boost p53 activity reduced tumor burden and improved survival in lab models. ow.ly/viW950XKzFw

This year, researchers advanced H5N1 research showing that the virus in dairy cattle retains avian features, posing low pandemic risk, and that pasteurized milk with inactive viral components is safe. Studies also identified key S. aureus virulence mechanisms in natural host models.

Regional Advisory Committees (RACs) recently met at the annual St. Jude Global Alliance Convening. Each RAC brings together leaders from member institutions and partner organizations across regions to guide strategy and ensure locally informed, relevant work.

St. Jude researchers developed Combocat, a machine learning-powered platform that rapidly screens drug combinations at scale. In a proof-of-principle test, 9,045 drug pairs were screened, uncovering new synergistic therapies. ow.ly/S5sZ50XJZyb

St. Jude welcomed over 120 Global Alliance members and stakeholders from more than 60 countries to campus, with 1,000+ joining virtually, for the annual convening. By ensuring every region’s voice is heard, the Alliance moves beyond planning to measurable progress.

As the year ends, we’re highlighting hematology innovations. A 13-year follow up showed gene therapy for hemophilia B remains safe & effective, while a study on CRISPR-based epigenetic editing reactivated fetal hemoglobin for sickle cell & beta-thalassemia.

St. Jude is proud to serve as a national leader in pediatric cancer research and care, as highlighted in the inaugural AACR Pediatric Cancer Progress Report, showcasing advances that are transforming treatment for children and adolescents. #AACR #PediatricCancer

Congratulations to Juan Barajas, PhD, for earning the Joanne Levy, MD, Memorial Award for Outstanding Achievement at the @ash.hematology.org Annual Meeting. His research identified a new XPO1 dependency in UBTF-TD AML, highlighting a potential therapeutic target for high-risk leukemia. #ASH25

Researchers developed IDR-Puncta ML, a machine learning model that predicts which intrinsically disordered protein regions can form biomolecular condensates. This resource advances understanding of condensate formation in cancer and RNA-related diseases. ow.ly/U1hG50XBAbn

A collaborative project led by St. Jude has established a comprehensive framework for standardizing spatial transcriptomics. The Spatial Touchstone project integrates publicly available imaging data with newly curated datasets across six tissue types. ow.ly/Ghrg50XBkr6

New research reveals how anti-epilepsy drugs interact with SV2A, a protein found in nearly all neurons and the target of therapies such as levetiracetam. This breakthrough could guide the development of more effective treatments. ow.ly/A7IP50XAcky

St. Jude scientists discovered mitoxyperilysis, a new cell death pathway triggered by inflammation and nutrient stress. This finding opens new possibilities for cancer therapies targeting damaged mitochondria and inflammatory cell death. ow.ly/wf9S50Xz8P0

Applications for the Master’s in Applied Biomedical Data Sciences are open for just one more week @stjuderesearch.bsky.social! applyweb.com/forms/stjudegr

t. Jude researchers developed TIRTL-seq, an innovative method for comprehensive and cost-effective T-cell receptor analysis. It processes 10 million cells at 10% of previous costs, helping accelerate immunology research and improve diagnostics. ow.ly/whO650XwV34

Dolores Irala, MD, Department of Cell & Molecular Biology, was featured in a symposium at @sfn.org Neuroscience 2025, discussing advances in research. Work like hers is how St. Jude is driving progress in cures and prevention for pediatric neurologic diseases.

Chemistry is central to drug discovery, enabling the efficient creation, analysis, and functional exploration of new molecules. At St. Jude, researchers are advancing each step to accelerate the search for new medicines.

Early-career scientists from St. Jude are presenting their latest findings at the @sfn.org Neuroscience 2025 conference in San Diego, covering topics from rare neurodevelopmental disorders to the molecular mechanisms underlying genetic mutations.

The St. Jude Shared Resources Expo highlighted 19 lab-based institutional shared resources available for researchers. By centralizing advanced technologies and expert staff, these facilities enable investigators to pursue innovative research and collaborate across disciplines.

The Pediatric Infectious Diseases Fellowship at St. Jude and @uthsc.bsky.social provides access to leading mentors, research opportunities and career development, preparing fellows to advance care of pediatrics infections with enhanced experience in caring for immunocompromised children.

HUGE congratulations to Miriam Dillard-Stroud for being recognized as a @stjuderesearch.bsky.social Living Our Values Ambassador! Miriam is a GREAT collaborator to everyone in the St. Jude community! This is a very well-deserved honor! 🥳🤩🙌

Nineteen St. Jude scientists have been named to the 2025 Highly Cited Researchers list, the most from St. Jude since the list began. This distinction identifies those whose publications rank in the top 1% for citations, indicating broad influence. ow.ly/HKIk50XrffV

St. Jude scientists have launched AlphaSync, a continuously updated database of predicted protein structures. AlphaSync bridges the gap left by previous resources, ensuring researchers access the most current models. ow.ly/UpUc50Xq7t7

Scientists at St. Jude and Northwestern University have uncovered how CRISPR-Cas9 gene therapy silences BCL11A in sickle cell disease and β-thalassemia. The therapy disrupts a 3D genome structure essential for BCL11A expression, reactivating fetal hemoglobin. ow.ly/to6w50XpI9H

A multi-national study co-led by St. Jude analyzed 164 cases of infant-type hemispheric glioma (IHG), providing the largest dataset to date. Findings set new benchmarks for clinical decision-making in this rare, aggressive pediatric brain tumor. ow.ly/F0oR50XpvN2

Translational researchers at St. Jude are advancing pediatric cancer care by moving promising compounds from the lab to clinical trials. This process starts with identifying molecular targets for hard-to-treat childhood cancers. ow.ly/AFNa50Xo1Ez

Researchers have mapped 117 kinases capable of phosphorylating the RNA polymerase II tail, revealing modifications at previously disregarded positions beyond amino acids two and five. This discovery expands our understanding of gene transcription control.

Scientists have discovered an alternative binding pocket on the pregnane X receptor (PXR), a nuclear receptor involved in drug metabolism. This finding unlocks possibilities for drug discovery related to nuclear receptors.

New research from St. Jude offers the most comprehensive analysis of medulloblastoma treatment to date, using clinical and molecular data from nearly 900 children. The findings help address the challenge of tailoring therapy to minimize long-term side-effects.

The Bringing Chemistry to Medicine symposium at St. Jude Children’s Research Hospital continues its remarkable growth, welcoming more than 1,000 attendees from 44 countries in 2025. Over six years, the symposium has reached over 3,000 participants from 73 countries.

Understanding the foundational factors affecting health—such as genetics and environment—enables more accurate prediction and prevention of disease in children. St. Jude is advancing detection and treatment to improve outcomes and quality of life.

New research reveals how tandem duplications in the UBTF gene create an abnormal transport signal, driving a high-risk, treatment-resistant subtype of acute myeloid leukemia (UBTF-TD AML). ow.ly/aYjp50XlQmW

It's Halloween 🎃 #FlourescenceFriday! Here is a microscopic pumpkin generated by showing a cell nucleus in 🟠 with the primary cilium "stem" in 🟢! I hope everyone has a spooky 👻 day! 🔬 by @stjuderesearch.bsky.social grad student Christina Wang. 🧪

Leaders at St. Jude joined experts worldwide at #SIOP2025 in Amsterdam, presenting topics ranging from advances in high-risk medulloblastoma to the future of chemotherapy-free childhood ALL treatment.